A Study of Avapritinib in Pediatric Patients With Solid Tumors Dependent on KIT or PDGFRA Signaling

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

February 24, 2022

Primary Completion Date

February 28, 2025

Study Completion Date

December 30, 2025

Conditions
Solid Tumor, Unspecified, ChildRelapsed Solid NeoplasmCNS Tumor
Interventions
DRUG

avapritinib

oral administration

Trial Locations (26)

1090

Medizinische Universitat Wein, Vienna

2031

Sydney Children's Hospital, Kids Cancer Center, Sydney

3052

Royal Children's Hospital, Parkville

10032

Columbia University Medical Center, New York

15224

UPMC Children's Hospital of Pittsburgh, Pittsburgh

20133

Dipartimento di Oncologia Medica ed Ematologia - S.C. Pediatria Oncologica, Milan

21287

The Johns Hopkins Hospital, Baltimore

27710

Duke University Medical Center, Durham

37075

Universitaetsmedizin Göttingen, Göttingen

43205

Nationwide Children's Hospital, Columbus

48109

University of Michigan, Ann Arbor

60611

Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago

63110

Washington University School of Medicine, St Louis

75235

Children's Medical Center, Dallas

77030

University of Texas MD Anderson Cancer Center, Houston

80045

Children's Hospital Colorado, Aurora

85016

Phoenix Children's Hospital, Phoenix

94518

University of California San Francisco, Benioff Children's Hospital, San Francisco

94805

Gustave Roussy, Villejuif

97239

Oregon Health and Science University, Portland

02215

Dana Farber Cancer Institute, Boston

M5G1X8

The Hospital for Sick Children, Toronto

Unknown

Hopp Children's Cancer Center, Heidelberg

05505

Asan Medical Center, Seoul

06351

Samsung Medial Center, Seoul

WC1N 3JH

Great Ormond Street Hospital For Children, London

All Listed Sponsors
lead

Blueprint Medicines Corporation

INDUSTRY

NCT04773782 - A Study of Avapritinib in Pediatric Patients With Solid Tumors Dependent on KIT or PDGFRA Signaling | Biotech Hunter | Biotech Hunter